-
Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation
•
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug conjugate (ADC), is on course to obtain breakthrough therapy designation (BTD) status from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of unresectable or metastatic breast cancer with low…
-
EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review
•
EOC Pharma, a biotech operating out of the US and China, has announced that a clinical trial filing for its CDK7 inhibitor EOC237 has been accepted for review by the Center for Drug Evaluation (CDE) in China. This marks a significant milestone in the development of EOC237, which is expected…
-
Joincare’s Generic Seretide Accepted for NMPA Review
•
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline’s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover…
-
Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership with US firm Mythic Therapeutics. The collaboration aims to leverage Nona’s HCAb transgenic mice platform technology and antibody discovery services to develop next-generation antibody-drug conjugates (ADCs) targeting multiple tumors. No financial details were disclosed. Partnership…
-
Everest Medicines’ Nefecon Included in South Korea’s GIFT Program
•
China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug Safety (MFDS) has included the firm’s Nefecon (targeted-release formulation-budesonide) in the Global Innovative Fast Track (GIFT) program for the treatment of primary immunoglobulin A nephropathy (IgAN). This designation is a significant step in the development…
-
Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion
•
China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826), a leading biomaterial firm focused on ophthalmology, medical aesthetics, wound care, orthopedics, and anti-adhesion and hemostasis, has announced the acquisition of a 20% stake in compatriot firm Shenzhen New Industries Material of Ophthalmology Co., Ltd (SZNIMO) for a consideration of RMB…
-
Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors
•
China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its HP530S, a highly active and selective focal adhesion kinase (FAK) inhibitor against solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development of…
-
AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth
•
UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca’s strong pipeline and…
-
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
•
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical drug candidate QLS12004 has obtained tacit clinical trial approval. This marks a significant step forward in the development of new treatments for solid tumors, including advanced breast cancer, which is the leading malignant cancer affecting…
-
Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for a previously planned initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This decision comes amidst considerations of the current market situation and corporate development planning. Reasons for TerminationSino Bio cited…
-
Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions
•
China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation, leveraging their respective advantages and integrating resources to comprehensively cooperate in the area of biochemical immune diagnosis overall solutions. This strategic collaboration aims to enhance the market presence of both companies in the diagnostic sector.…
-
GenScript ProBio Partners with Bio Immunitas for hRPP Platform
•
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a long-term partnership with UK-based Bio Immunitas, a firm built around a proprietary human Recombinant Protein Platform (hRPP). This strategic collaboration aims to accelerate Bio Immunitas’s manufacturing capabilities from the lab to clinic, including IND-enabling CMC…
-
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
•
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011 IT, has produced positive signs of efficacy as a treatment for melanoma in late-stage patients who have failed previous immunotherapy. In a Phase II clinical study conducted in China and the United States, monotherapy treatment…
-
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
•
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and oncology, has announced the completion of a Series D financing round at close to RMB 300 million (USD 44.18 million). This significant funding round was led by Hongfu Investment, with contributions from Jihan Capital, Hainan…
-
Neurodawn Completes Series A+ Financing for CNS Drug Development
•
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has announced the completion of a Series A+ financing round in excess of RMB 100 million (USD 14.73 million). The round was led by China Merchants Health, with existing investor Simcere Pharmaceutical Group (HKG: 2096) participating.…
-
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment and dosing in the Phase Ib REFINE study for its drug candidate STC3141 in sepsis in Australia and Belgium. The first data readout is expected in four months’ time, marking a significant milestone in the…
-
Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering
•
Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional approval from the SIX Swiss Exchange to make a public offering of an undisclosed amount of Global Depositary Receipts (GDR) on the bourse. This marks a significant step in the company’s international expansion and capital…
-
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
•
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244) and Tigermed (SHE: 300347, HKG: 3347), has struck a partnership with Belgium-headquartered Cerba Healthcare’s subsidiary Cerba Research. The two companies will set up a JV in Wuxi, Jiangsu Province, China, marking a significant expansion of…
-
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
•
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply issues, prompting the company to seek additional production and supply agreements. The latest deal was struck with Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), following a similar agreement with Zhejiang Huahai Pharmaceutical Co., Ltd (SHA:…
-
Macrolux Secures Series A Funding for Endoscopy Solutions
•
Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB 100 million (USD 14.75 million) in a Series A financing round. This significant capital injection will support the company’s efforts to provide solutions better tailored to customer needs globally. Financing DetailsThe Series A round was…
